Archivio Istituzionale della RicercaDespite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index). The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo-immunotherapy followed by autologous transplantation in frontline MCL patients <66 years.[Ladetto, ASH 2018] Several biological ancillary studies were planned upfront, prospectively investigating the prognostic impact of putative biomarkers. Here we present a comprehensive analysis of the clinical impact of all the identified biopredictors.
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL / Ferrero, S., Zaccaria, G.M., Barbero, D., Evangelista, A., Di Rocco, A., Re, A., Stefoni, V., Cavallo, F., Vitolo, U., Balzarotti, M., Rusconi, C., da Silva, G.M., Ghislieri, M., Omedè, P., Zamò, A., Ciccone, G., Gattei, V., Gaidano, G., Cortelazzo, S., Ladetto, M.. - In: HEMASPHERE. - ISSN 2572-9241. - ELETTRONICO. - 3:(2019), pp. 569-570. (European Hematology Association (EHA) Amsterdam 13/06/2019 - 16/06/2019) [10.1097/01.HS9.0000563272.02759.6b].
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL
Ghislieri, M.;
2019
Abstract
Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index). The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo-immunotherapy followed by autologous transplantation in frontline MCL patients <66 years.[Ladetto, ASH 2018] Several biological ancillary studies were planned upfront, prospectively investigating the prognostic impact of putative biomarkers. Here we present a comprehensive analysis of the clinical impact of all the identified biopredictors.
| File | Dimensione | Formato | |
|---|---|---|---|
|
COMPREHENSIVE_ANALYSIS_OF_BASELINE_OUTCOME.1134.pdf
accesso aperto
Tipologia:
2a Post-print versione editoriale / Version of Record
Licenza:
Pubblico - Tutti i diritti riservati
Dimensione
602.72 kB
Formato
Adobe PDF
|
602.72 kB | Adobe PDF | Visualizza/Apri |
|
EHA_2019_Ferrero.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Pubblico - Tutti i diritti riservati
Dimensione
2.7 MB
Formato
Adobe PDF
|
2.7 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11583/2762893
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo